Professor rocky | together: treatment of prostate cancer development and prospect of MDT mode

2022-04-30 0 By

“An” Medical “Happy Industry” is a humanistic case collection project jointly organized by Beijing Chen Jumei Public Welfare Foundation and Medical Maitong.The series of urology physician interviews will focus on the field of prostate cancer, discuss the significance of standardized diagnosis and treatment path and whole course management of prostate cancer for clinical patients based on the real clinical needs, and highlight the research spirit and professional quality of urology oncologists.Prostate cancer is now the second most common cancer in men worldwide, after lung cancer.Patients with prostate cancer incidence is increasing in our country, the installment, the burden is heavy, late of early prostate cancer diagnosis and comprehensive and systematic treatment of the long-term prognosis of patients. There is, therefore, by screening, early accurate diagnosis and comprehensive treatment of prostate cancer derived integration of multi-disciplinary treatment (MDT) construction is very necessary.In this issue, we have invited Professor Huang Yi from Peking University Third Hospital to talk about the crucial role of MDT model in promoting the development of precision therapy for prostate cancer, the development of MDT model for prostate cancer treatment, and the outlook for the future.Introduction of expert professor huang yi, director of the physician Doctoral tutor professor of Peking University third hospital urological surgery of Chinese medical association branch of the tumor group members of Beijing medical association uropoiesis surgical department branch of the Beijing medical association uropoiesis surgical department branch tumor group member standing committee of the Beijing health promoting the uropoiesis surgical department branch multidisciplinary treatment pattern beginning to promote early screening rocky professor pointed out that in recent years,The incidence of prostate cancer in China is increasing year by year, and many patients often come to the doctor after bone metastasis, fracture, bone pain, hematuria and other symptoms. At this time, patients have reached the advanced stage, which is very unfavorable for their treatment.”At present, more than 60% to 70% of domestic prostate cancer patients are detected as locally advanced or metastatic advanced, which requires us to gradually promote the early screening of prostate cancer.””What we are doing is far from enough,” Huang said.The CSCO guidelines recommend that men over the age of 50, or those over the age of 45 with a family history of cancer, be included in the high-risk group for prostate cancer and be screened for PSA every two years;At the same time, Huang yi believes that the promotion of community physical examination and scientific publicity can help promote the early detection of prostate cancer.Improve the high risk population by screening the detection rate of prostate cancer, can significantly reduce the incidence of metastatic prostate cancer and mortality, screening, early detection, early treated early is to improve the 5-year survival rate in patients with prostate cancer, one of the most effective ways at the same time actively carry out MDT mode of comprehensive treatment, can bring the biggest benefit for patients.Multidisciplinary joint diagnosis and treatment (MDT) is a treatment model that puts forward individualized and optimal treatment plans for difficult diseases after centralized discussion by multidisciplinary experts.Rocky professor think that the advantage of MDT mode, aiming at middle-late tumor such a complex disease, usually involves multi-disciplinary combination therapy, single specialist experts is very difficult to master this kind of complex diseases comprehensive treatment, it is difficult to achieve the ideal treatment effect, but by MDT mode will be the experts in related disciplines together, according to individual patients,Individualized treatment can maximize the benefit of patients.Taking the MDT model of prostate cancer as an example, Professor Huang Yi introduced that the classical treatment methods for prostate cancer include surgery, internal radiotherapy, external radiotherapy and endocrine therapy. Patients with castration-resistant prostate cancer (CRPC) can also be combined with chemotherapy, nuclide therapy, targeted therapy and immunotherapy.For different stages and stages of prostate cancer, there are different combination methods and sequential treatment schemes, which can achieve synergistic and optimal treatment effect.MDT model can be based on the characteristics of prostate cancer, precise stratification, the development of individual combined treatment plan.In establishing the MDT model for prostate cancer, Professor Huang Yi gave the example of Peking University Third Hospital.In order to guarantee the MDT can play the biggest benefit, in addition to regularly carry out the multidisciplinary consultation and discussion, Peking University third hospital in recent years also on MDT group unified management according to the standard and procedure, to access the review, review process, and regular assessment, to require multidisciplinary treatment of advanced prostate cancer, relevant departments have fixed expert team, on a regular basis to discuss,Give the best comprehensive treatment plan.At the same time, the Urology department of Peking University Third Hospital also carried out MDT mode of continuing education classes, invited MDT team experts to theoretical lectures, surgical demonstrations, case discussions, etc., in order to promote and learn from each other, and then promote and popularize the MDT mode of treatment.”The MDT model is particularly well suited for the diagnosis and treatment of tumors, because many of these tumors do require multiple combinations of treatments, requiring a multidisciplinary team of experts to do the treatment.””But the MDT model needs to be further promoted in China, and we still have a lot of work to do in this regard,” Huang said.The longer the “front”, the greater the challenge, clinical treatment of prostate cancer in the future is rocky, says prof overall survival of patients with prostate cancer, even patients with advanced, comprehensive treatment or for most also can reach more than 5 years, therefore, often need to use it as a slow disease clinically, patients with established database, regular follow-up.For these patients, how to manage, follow up, and develop different treatment plans according to the different stages of patients are the current and future challenges facing clinicians.However, compared with other urinary tumors, the treatment progress of prostate cancer is the fastest, and the research and investment of new clinical drugs for prostate cancer is also very large at home and abroad.Professor Huang Yi pointed out that prostate cancer has strong tumor heterogeneity, and the future development trend of prostate cancer treatment is more individual, more precise and refined treatment.With the wide application of high-throughput second-generation genome sequencing and bioinformation big data analysis, molecular stratification and precision treatment of tumors can be performed.For example, for prostate cancer, detection of susceptibility genes and various treatment pathways can be carried out, and the detection results can provide precise treatment choices for clinicians. In this way, patients can benefit the most with the minimum investment of resources and achieve the best treatment effect.At the end of the summary, Professor Huang Yi also put forward his own suggestions for clinicians who have just entered the field of urology.He believes that for urologists, the first is to strengthen the study of the basic theory and basic technology of diseases related to urology, and understand the basic laws of diseases in this discipline;On this basis, they should also actively expand their knowledge, including understanding the progress of relevant disciplines, as far as possible to absorb the relevant knowledge of multiple disciplines, and improve their comprehensive quality and comprehensive diagnosis and treatment ability of diseases.”In medicine, one does not become an expert in one day or two, but through years of accumulation, continuous learning, continuous practice.Only in the process of repeated improvement, can you further improve yourself, which is a relatively long process.”Professor Huang Yi concluded.Special thanks: Beijing Astellas Pharmaceutical Co., LTD